We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

OptiBiotix Health plc (OPTI) Ord 2p

Sell:11.00p Buy:11.50p 0 Change: 1.00p (8.16%)
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:11.00p
Buy:11.50p
Change: 1.00p (8.16%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:11.00p
Buy:11.50p
Change: 1.00p (8.16%)
Market closed |  Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OcptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiomeX3, SlimBiome Medical and WellBiome.

Contact details

Address:
Innovation Centre
Innovation Way, Heslington
HESLINGTON
Y010 5DG
United Kingdom
Telephone:
+44 (020) 79338780
Website:
www.optibiotix.com

Important dates

Future events
There are no future events available.
Past events
Interim results 27 September 2024 27/09/24
AGM 08 August 2024 08/08/24

General stock information

EPIC:
OPTI
ISIN:
GB00BP0RTP38
Market cap:
£11.02 million
Shares in issue:
97.94 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Stephen O'Hara
    Chief Executive Officer, Executive Director
  • Graham Myers
    Executive Director - Finance Director
  • David Blain
    Acting Finance Director
  • Sofia Kolyda
    Executive Director - Research and Development Director
  • Mark Collingbourne
    Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.